GLP-1 Receptor Agonists: Class Overview Monograph

Pharmacology and Mechanism of Action

GLP-1 receptor agonists mimic the endogenous incretin hormone glucagon-like peptide-1, binding to GLP-1 receptors on pancreatic beta cells to amplify glucose-dependent insulin secretion. They simultaneously suppress glucagon release from alpha cells, slow gastric emptying, and activate hypothalamic satiety centers. The glucose-dependent nature of insulin stimulation means hypoglycemia risk is low when these agents are used without sulfonylureas or insulin.

Receptor Binding and Signal Transduction

Native GLP-1 has a plasma half-life of roughly 2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Synthetic GLP-1 RAs achieve clinical utility through structural modifications that resist DPP-4 cleavage. Exenatide, derived from exendin-4 (a peptide found in Gila monster saliva), shares 53% amino acid homology with human GLP-1 and resists DPP-4 through a glycine substitution at position 2 1. Liraglutide and semaglutide are acylated human GLP-1 analogues. A C-16 fatty acid chain on liraglutide enables albumin binding that extends its half-life to approximately 13 hours, while semaglutide's C-18 fatty diacid side chain and an aminoisobutyric acid substitution at position 8 extend its half-life to roughly 165 hours 2.

Central and Peripheral Actions

Beyond the pancreas, GLP-1 receptors are expressed in the area postrema, nucleus tractus solitarius, and hypothalamic arcuate nucleus. Activation of these receptors reduces appetite and food intake. GLP-1 RAs also slow gastric emptying, though tachyphylaxis to this effect occurs with long-acting agents. Short-acting agents like exenatide twice daily and lixisenatide retain more gastric-slowing effect, which produces greater postprandial glucose reduction but less fasting glucose lowering compared to long-acting agents 3.

Approved Agents and Formulations

Six distinct GLP-1 RA molecules have received FDA approval, though albiglutide (Tanzeum) was voluntarily withdrawn from the market in 2018 for commercial reasons. The remaining five agents differ in dosing frequency, route, and approved indications.

Short-Acting Agents

Exenatide immediate-release (Byetta) is injected subcutaneously twice daily within 60 minutes before meals. Lixisenatide (Adlyxin) is a once-daily prandial agent approved for type 2 diabetes. Both short-acting agents produce postprandial glucose excursion reductions of 4 to 6 mmol/L but have modest effects on fasting glucose and HbA1c (reductions of 0.8 to 1.0 percentage points) 4.

Long-Acting Injectable Agents

Exenatide extended-release (Bydureon) uses microsphere technology for once-weekly dosing. Dulaglutide (Trulicity) is a GLP-1 analogue fused to a modified IgG4 Fc fragment, also dosed weekly. Semaglutide (Ozempic) is the most potent weekly injectable GLP-1 RA, with HbA1c reductions of 1.5 to 1.8 percentage points at the 1.0 mg dose in SUSTAIN trials 5.

Oral Formulation

Oral semaglutide (Rybelsus) uses a co-formulated absorption enhancer (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate, or SNAC) to protect the peptide from gastric degradation and promote transcellular absorption across gastric epithelium. Bioavailability is approximately 0.4 to 1%. Patients must take it on an empty stomach with no more than 120 mL of water, then wait at least 30 minutes before eating or taking other oral medications 6. The 14 mg dose produced HbA1c reductions of 1.3 percentage points in PIONEER-1 (N=703) 7.

Approved Indications

Liraglutide holds dual indications: Victoza (1.2 and 1.8 mg) for type 2 diabetes, and Saxenda (3.0 mg) for chronic weight management in adults with BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity. Semaglutide similarly has diabetes indications (Ozempic 0.5, 1.0, and 2.0 mg; Rybelsus 7 and 14 mg) and a dedicated obesity indication (Wegovy at 2.4 mg weekly) 8. Dulaglutide, exenatide, and lixisenatide are approved only for type 2 diabetes.

The 2022 ADA Standards of Care recommend GLP-1 RAs as first-line injectable therapy for type 2 diabetes, preferred over basal insulin in most patients, and specifically recommend agents with proven cardiovascular benefit (liraglutide, semaglutide, dulaglutide) for patients with established atherosclerotic cardiovascular disease.

Landmark Cardiovascular and Weight Outcomes Trials

The cardiovascular safety and efficacy of GLP-1 RAs has been established through a series of large, randomized, placebo-controlled outcomes trials mandated by the FDA after 2008.

LEADER and SUSTAIN-6

LEADER (N=9,340) randomized patients with type 2 diabetes and high cardiovascular risk to liraglutide 1.8 mg daily versus placebo for a median of 3.8 years. The primary 3-point MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 13.0% of the liraglutide group versus 14.9% with placebo (HR 0.87, 95% CI 0.78 to 0.97, P=0.01), with a significant reduction in cardiovascular mortality 9. SUSTAIN-6 (N=3,297) showed semaglutide 0.5 and 1.0 mg reduced MACE by 26% versus placebo (HR 0.74, 95% CI 0.58 to 0.95, P=0.02), driven primarily by a 39% reduction in nonfatal stroke 10.

REWIND and SELECT

REWIND (N=9,901) studied dulaglutide 1.5 mg weekly in a broader population (only 31% had established cardiovascular disease at baseline). Over a median follow-up of 5.4 years, dulaglutide reduced MACE by 12% (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) 11.

SELECT (N=17,604) was the first cardiovascular outcomes trial conducted exclusively in patients with overweight or obesity without diabetes. Semaglutide 2.4 mg weekly reduced MACE by 20% over a mean follow-up of 39.8 months (HR 0.80, 95% CI 0.72 to 0.90, P<0.001) 12. The American Heart Association called SELECT "a approach-defining trial demonstrating that treating obesity itself reduces cardiovascular events independent of diabetes status."

EXSCEL and ELIXA

Not all GLP-1 RAs have shown cardiovascular superiority. EXSCEL (N=14,752) with exenatide extended-release met noninferiority but not superiority for MACE (HR 0.91, 95% CI 0.83 to 1.00, P=0.06 for superiority) 13. ELIXA (N=6,068) with lixisenatide was neutral (HR 1.02) 14. These results inform formulary positioning, as agents with proven MACE reduction carry a clinical advantage in high-risk populations.

Weight Loss Efficacy Across Agents

Weight reduction varies substantially across the class. The dose-response relationship is steep.

Diabetes Populations

In type 2 diabetes trials, mean weight loss ranges from 1.5 to 2.0 kg with lixisenatide, 2.5 to 3.5 kg with dulaglutide 1.5 mg, 3.0 to 4.0 kg with liraglutide 1.8 mg, and 4.5 to 6.5 kg with semaglutide 1.0 mg over 30 to 56 weeks 5.

Obesity Populations

At dedicated obesity doses, weight loss is more pronounced. In STEP-1 (N=1,961), semaglutide 2.4 mg weekly produced 14.9% mean body weight reduction at 68 weeks versus 2.4% with placebo 15. Liraglutide 3.0 mg (Saxenda) produced 8.0% weight loss versus 2.6% with placebo in SCALE Obesity and Prediabetes (N=3,731) at 56 weeks 16.

A clinically useful hierarchy for expected weight loss by agent, ranked from greatest to least at maximum approved dose: semaglutide 2.4 mg (14 to 15%) > liraglutide 3.0 mg (7 to 8%) > dulaglutide 4.5 mg (4 to 5%) > exenatide ER 2 mg (2 to 3%) > lixisenatide 20 mcg (1 to 2%).

Renal Outcomes

The FLOW trial (N=3,533) randomized patients with type 2 diabetes and CKD (eGFR 25 to 75 mL/min/1.73 m² with UACR 100 to 5,000 mg/g) to semaglutide 1.0 mg weekly versus placebo. The trial was stopped early for efficacy at a median of 3.4 years. Semaglutide reduced the primary composite renal endpoint (sustained ≥50% eGFR decline, kidney failure, renal death, or cardiovascular death) by 24% (HR 0.76, 95% CI 0.66 to 0.88, P=0.0003) 17. This positions semaglutide as the first GLP-1 RA with a dedicated renal outcomes indication.

No dose adjustment is required for any GLP-1 RA in mild-to-moderate renal impairment. Exenatide is not recommended when eGFR falls below 30 mL/min/1.73 m². Liraglutide, dulaglutide, and semaglutide may be used in severe CKD with monitoring, though gastrointestinal side effects can worsen dehydration risk 18.

Safety and Adverse Effect Profile

Gastrointestinal Effects

Nausea is the most common adverse effect, occurring in 15 to 44% of patients depending on the agent and dose. It is typically transient, peaking during dose escalation and resolving within 4 to 8 weeks. Vomiting occurs in 5 to 15%. Gradual dose titration reduces GI intolerance substantially. The Endocrine Society 2023 clinical practice guideline recommends extending titration intervals if nausea persists beyond 2 weeks at a given dose.

Pancreatitis and Pancreatic Safety

Acute pancreatitis has been reported at rates of 0.1 to 0.3% across GLP-1 RA trials, compared to 0.1 to 0.2% with placebo. A 2023 meta-analysis of 7 cardiovascular outcomes trials (N=56,004) found no significant increase in pancreatitis risk with GLP-1 RAs (OR 1.01, 95% CI 0.73 to 1.39) 19. GLP-1 RAs should still be discontinued if pancreatitis is suspected and not restarted after a confirmed episode.

Thyroid Safety

All GLP-1 RAs carry a boxed warning regarding medullary thyroid carcinoma (MTC) based on rodent studies showing C-cell hyperplasia and tumors with long-term exposure. Human relevance remains uncertain. Rodent C-cells express GLP-1 receptors at high density, while human C-cell GLP-1 receptor expression is minimal. A retrospective analysis of FDA Adverse Event Reporting System data and Scandinavian cancer registries with over 1.2 million patient-years of exposure has not shown a signal for MTC in humans 20. The contraindication in patients with personal or family history of MTC or MEN2 remains absolute.

Gallbiliary Events

Cholelithiasis risk increases with rapid weight loss. In STEP trials, gallbladder-related events occurred in 1.6% of semaglutide-treated patients versus 0.7% with placebo. Patients losing more than 1.5 kg per week during titration warrant counseling about gallstone symptoms.

Retinopathy

SUSTAIN-6 observed a significant increase in retinopathy complications with semaglutide (HR 1.76, 95% CI 1.11 to 2.78), though this was likely related to rapid HbA1c reduction in patients with pre-existing retinopathy rather than a direct drug effect 10. The FOCUS trial (N=1,515) subsequently demonstrated that semaglutide 1.0 mg did not worsen diabetic retinopathy over 2 years compared to placebo in patients with baseline non-proliferative retinopathy 21.

Dosing and Titration

All injectable GLP-1 RAs require dose titration to minimize gastrointestinal adverse effects. Titration schedules vary.

Semaglutide Injectable (Ozempic)

Start at 0.25 mg weekly for 4 weeks (titration dose only, not therapeutic), increase to 0.5 mg for at least 4 weeks, then to 1.0 mg. If additional glycemic control is needed after at least 4 weeks on 1.0 mg, increase to 2.0 mg weekly. For the obesity indication (Wegovy), the titration spans 16 weeks: 0.25 mg for 4 weeks, 0.5 mg for 4 weeks, 1.0 mg for 4 weeks, 1.7 mg for 4 weeks, then the maintenance dose of 2.4 mg weekly 8.

Liraglutide

Victoza: start at 0.6 mg daily for one week, increase to 1.2 mg. May increase to 1.8 mg if needed. Saxenda: start at 0.6 mg daily, increasing by 0.6 mg weekly over 5 weeks to the target 3.0 mg daily dose. Discontinue if the patient has not lost at least 4% of baseline body weight by 16 weeks.

Dulaglutide

Start at 0.75 mg weekly, increase to 1.5 mg after 4 weeks. May further increase to 3.0 mg and then 4.5 mg at 4-week intervals for additional glycemic benefit.

Drug Interactions and Prescribing Considerations

GLP-1 RAs have relatively few pharmacokinetic drug interactions because they are peptides cleared through proteolytic degradation rather than hepatic CYP metabolism. The primary interaction concern is pharmacodynamic.

Delayed gastric emptying (most relevant with short-acting agents) may affect absorption of concomitant oral medications. Oral contraceptives, antibiotics, and drugs with narrow therapeutic indices should be taken at least 1 hour before GLP-1 RA injection or at a time when the gastric-slowing effect is minimal 3.

Combining GLP-1 RAs with sulfonylureas or insulin increases hypoglycemia risk. The ADA recommends reducing the sulfonylurea dose by 50% or the basal insulin dose by 20% when initiating a GLP-1 RA 22.

GLP-1 RAs should not be combined with DPP-4 inhibitors, as both act through incretin pathways and the combination provides no additional efficacy while increasing cost 22.

Clinical Selection: Choosing Among Agents

Agent selection should integrate three considerations: the primary treatment target (glucose, weight, or cardiovascular risk), patient preference regarding injection frequency and route, and formulary access.

For patients with established ASCVD or high cardiovascular risk, prescribers should select an agent with proven MACE benefit: liraglutide, semaglutide, or dulaglutide. Semaglutide has the largest effect size for both MACE reduction and weight loss. For patients with CKD, semaglutide is the only GLP-1 RA with dedicated renal outcomes data from FLOW.

For patients whose primary goal is weight management, semaglutide 2.4 mg (Wegovy) produces the greatest weight loss among approved single-target GLP-1 RAs. Liraglutide 3.0 mg (Saxenda) is an alternative for patients who cannot access or tolerate semaglutide.

For patients who prefer a non-injectable option, oral semaglutide (Rybelsus) is the only choice within the class. Its strict fasting requirements may reduce adherence in some patients.

Dr. John Buse, Director of the UNC Diabetes Center, noted in a 2023 ADA symposium: "The GLP-1 receptor agonist class has moved from a second-line diabetes therapy to a first-line cardiometabolic platform. We now treat the patient's entire risk profile, not just the glucose number."

Emerging Data and Pipeline Considerations

High-dose oral semaglutide (25 and 50 mg) showed HbA1c reductions of 2.0 percentage points and weight loss of up to 15.1% in PIONEER PLUS (N=1,606), approaching injectable efficacy 23. These higher oral doses are under regulatory review and could shift prescribing patterns toward oral-first approaches.

The dual GIP/GLP-1 agonist tirzepatide (Mounjaro, Zepbound) and the triple GIP/GLP-1/glucagon agonist retatrutide represent next-generation incretin therapies that build on GLP-1 RA pharmacology but are classified separately due to their multi-receptor activity.

Semaglutide is being studied for MASH/NASH (ESSENCE trial), heart failure with preserved ejection fraction (STEP-HFpEF showed a 7.8-point improvement in KCCQ-CSS versus 2.3 with placebo, P<0.001) 24, and obstructive sleep apnea, expanding the clinical footprint well beyond glucose lowering.

Prescribers initiating a GLP-1 RA should document baseline body weight, HbA1c, eGFR, lipid panel, and retinal exam status, then reassess at 3 and 6 months to confirm therapeutic response and guide dose optimization.